Due to the heterogeneous safety profiles of different CDK4/6 inhibitors inrelation to cardiovascular events, coupled with a lack of head-to-head trialscomparing these drugs, we aimed to qualitatively synthesize the incidence ofmajor adverse cardiovascular events (MACE) and hypertension associated with theuse of CDK4/6 inhibitors reported in RCTs. The gene discussed is CDK4; the disease is Hypertension.